Twitter/X

Intercept is a $500 million philanthropic initiative launched by Nan Ransohoff…

2026-06-24 · 17:32 UTC ·@mhdempsey ·1 min read

Brief

Nan Ransohoff announced Intercept on 2026-06-24, a $500M philanthropic effort to eliminate respiratory infections by funding broad-spectrum preventatives and air-cleaning technologies. She highlights a global burden—5% of life sick, ~1M deaths/year, $600B lost—and says a convening of ~40 experts found technical complexity and sustained funding gaps are the main obstacles.

Why it matters

Intercept is a $500 million philanthropic initiative launched by Nan Ransohoff (announced 2026-06-24) to make respiratory infections — including the common cold and flu — a thing of the past by catalyzing development of broad-spectrum preventatives and air-cleaning technologies.

Key details

  • Ransohoff cites the scale of the problem: most people will spend 5% of their lives sick from respiratory viruses, these infections kill ~1,000,000 people per year, and cost about $600 billion annually in lost productivity.
  • Last year Ransohoff convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts who identified two barriers: (1) technical difficulty — hundreds of distinct, mutating strains across several families, though recent breakthroughs make broad-spectrum approaches more feasible; (2) chronic underfunding (COVID funding was a temporary spike). Anchor funders include Stripe, Anthropic, TheFluLab, FoundationOAI and individuals from Jane Street; the team includes incredutility.
Source evidence

This is so great.

Nan Ransohoff (@nanransohoff)

Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past.

We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics.

So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that.

We heard two main reasons:
(1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible.
(2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained).

We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies.

This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot.

We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street.

And, I’m very excited to be building this with @incredutility and the rest of the team.

— https://nitter.net/nanransohoff/status/2069761661456601188#m